Literature DB >> 33428075

CCN2 (Cellular Communication Network factor 2) in the bone marrow microenvironment, normal and malignant hematopoiesis.

Roos J Leguit1, Reinier A P Raymakers2, Konnie M Hebeda3, Roel Goldschmeding4.   

Abstract

CCN2, formerly termed Connective Tissue Growth Factor, is a protein belonging to the Cellular Communication Network (CCN)-family of secreted extracellular matrix-associated proteins. As a matricellular protein it is mainly considered to be active as a modifier of signaling activity of several different signaling pathways and as an orchestrator of their cross-talk. Furthermore, CCN2 and its fragments have been implicated in the regulation of a multitude of biological processes, including cell proliferation, differentiation, adhesion, migration, cell survival, apoptosis and the production of extracellular matrix products, as well as in more complex processes such as embryonic development, angiogenesis, chondrogenesis, osteogenesis, fibrosis, mechanotransduction and inflammation. Its function is complex and context dependent, depending on cell type, state of differentiation and microenvironmental context. CCN2 plays a role in many diseases, especially those associated with fibrosis, but has also been implicated in many different forms of cancer. In the bone marrow (BM), CCN2 is highly expressed in mesenchymal stem/stromal cells (MSCs). CCN2 is important for MSC function, supporting its proliferation, migration and differentiation. In addition, stromal CCN2 supports the maintenance and longtime survival of hematopoietic stem cells, and in the presence of interleukin 7, stimulates the differentiation of pro-B lymphocytes into pre-B lymphocytes. Overexpression of CCN2 is seen in the majority of B-acute lymphoblastic leukemias, especially in certain cytogenetic subgroups associated with poor outcome. In acute myeloid leukemia, CCN2 expression is increased in MSCs, which has been associated with leukemic engraftment in vivo. In this review, the complex function of CCN2 in the BM microenvironment and in normal as well as malignant hematopoiesis is discussed. In addition, an overview is given of data on the remaining CCN family members regarding normal and malignant hematopoiesis, having many similarities and some differences in their function.

Entities:  

Keywords:  Bone marrow; CCN2; CTGF; Connective tissue growth factor; Hematopoiesis; Leukemogenesis

Year:  2021        PMID: 33428075      PMCID: PMC7798015          DOI: 10.1007/s12079-020-00602-2

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  317 in total

Review 1.  Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.

Authors:  Archana Agarwal; Kerry Morrone; Matthias Bartenstein; Zhizhuang Joe Zhao; Amit Verma; Swati Goel
Journal:  Stem Cell Investig       Date:  2016-02-26

2.  Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer.

Authors:  Takuma Aikawa; Jason Gunn; Suzanne M Spong; Stephen J Klaus; Murray Korc
Journal:  Mol Cancer Ther       Date:  2006-05       Impact factor: 6.261

3.  Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts.

Authors:  D J Abraham; X Shiwen; C M Black; S Sa; Y Xu; A Leask
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

4.  Metabolic regulation of the CCN family genes by glycolysis in chondrocytes.

Authors:  Sho Akashi; Takashi Nishida; Abdellatif El-Seoudi; Masaharu Takigawa; Seiji Iida; Satoshi Kubota
Journal:  J Cell Commun Signal       Date:  2017-11-11       Impact factor: 5.782

5.  Connective tissue growth factor antibody therapy attenuates hyperoxia-induced lung injury in neonatal rats.

Authors:  Deepthi Alapati; Min Rong; Shaoyi Chen; Dorothy Hehre; Maria M Rodriguez; Kenneth E Lipson; Shu Wu
Journal:  Am J Respir Cell Mol Biol       Date:  2011-06-09       Impact factor: 6.914

6.  Connective tissue growth factor in human liver cirrhosis.

Authors:  M Abou-Shady; H Friess; A Zimmermann; F F di Mola; X Z Guo; H U Baer; M W Büchler
Journal:  Liver       Date:  2000-07

Review 7.  Regulation of hematopoietic stem cells by bone marrow stromal cells.

Authors:  Bryan A Anthony; Daniel C Link
Journal:  Trends Immunol       Date:  2013-11-05       Impact factor: 16.687

8.  Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta.

Authors:  José G Abreu; Nan I Ketpura; Bruno Reversade; E M De Robertis
Journal:  Nat Cell Biol       Date:  2002-08       Impact factor: 28.824

9.  The regenerative effects of CCN2 independent modules on chondrocytes in vitro and osteoarthritis models in vivo.

Authors:  Tarek Abd El Kader; Satoshi Kubota; Takashi Nishida; Takako Hattori; Eriko Aoyama; Danilo Janune; Emilio S Hara; Mitsuaki Ono; Yasuhiko Tabata; Takuo Kuboki; Masaharu Takigawa
Journal:  Bone       Date:  2013-11-20       Impact factor: 4.398

10.  Deep imaging of bone marrow shows non-dividing stem cells are mainly perisinusoidal.

Authors:  Melih Acar; Kiranmai S Kocherlakota; Malea M Murphy; James G Peyer; Hideyuki Oguro; Christopher N Inra; Christabel Jaiyeola; Zhiyu Zhao; Katherine Luby-Phelps; Sean J Morrison
Journal:  Nature       Date:  2015-09-23       Impact factor: 49.962

View more
  3 in total

Review 1.  The role of CCNs in controlling cellular communication in the tumor microenvironment.

Authors:  Lauren B Birkeness; Snigdha Banerjee; Mohiuddin Quadir; Sushanta K Banerjee
Journal:  J Cell Commun Signal       Date:  2022-06-08       Impact factor: 5.908

Review 2.  The CCN axis in cancer development and progression.

Authors:  Herman Yeger; Bernard Perbal
Journal:  J Cell Commun Signal       Date:  2021-04-20       Impact factor: 5.782

Review 3.  The Emerging Roles of CCN3 Protein in Immune-Related Diseases.

Authors:  Linan Peng; Yingying Wei; Yijia Shao; Yi Li; Na Liu; Lihua Duan
Journal:  Mediators Inflamm       Date:  2021-05-18       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.